Karuna Therapeutics, Inc.
KRTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $654 | $10,637 | $36,964 | $0 |
| % Growth | -93.9% | -71.2% | – | – |
| Cost of Goods Sold | $1,701 | $1,112 | $506 | $145 |
| Gross Profit | -$1,047 | $9,525 | $36,458 | -$145 |
| % Margin | -160.1% | 89.5% | 98.6% | – |
| R&D Expenses | $364,101 | $224,247 | $128,200 | $43,408 |
| G&A Expenses | $131,330 | $76,066 | $52,617 | $28,408 |
| SG&A Expenses | $131,330 | $76,066 | $52,617 | $28,408 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $588 | $580 | $254 | $0 |
| Operating Expenses | $495,431 | $300,313 | $180,817 | $71,816 |
| Operating Income | -$494,777 | -$289,676 | -$143,853 | -$71,816 |
| % Margin | -75,654% | -2,723.3% | -389.2% | – |
| Other Income/Exp. Net | $61,767 | $14,758 | $54 | $3,305 |
| Pre-Tax Income | -$433,010 | -$274,918 | -$143,799 | -$68,511 |
| Tax Expense | $670 | $1,418 | $6 | $43 |
| Net Income | -$433,680 | -$276,336 | -$143,805 | -$68,554 |
| % Margin | -66,311.9% | -2,597.9% | -389% | – |
| EPS | -11.73 | -8.74 | -4.94 | -2.59 |
| % Growth | -34.2% | -76.9% | -90.7% | – |
| EPS Diluted | -11.73 | -8.74 | -4.94 | -2.59 |
| Weighted Avg Shares Out | 36,959 | 31,629 | 29,139 | 26,446 |
| Weighted Avg Shares Out Dil | 36,959 | 31,629 | 29,139 | 26,446 |
| Supplemental Information | – | – | – | – |
| Interest Income | $61,179 | $14,178 | $502 | $3,305 |
| Interest Expense | $0 | $14,178 | $0 | $0 |
| Depreciation & Amortization | $1,701 | $1,112 | $702 | $3,305 |
| EBITDA | -$493,076 | -$259,628 | -$143,151 | -$68,511 |
| % Margin | -75,393.9% | -2,440.8% | -387.3% | – |